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1. Introduction 
 
Valvular heart disease represents a major cause of morbidity and mortality worldwide (1, 2). 
Besides conventional therapy concepts based on surgical repair or replacement, 
transcatheter valve implantation techniques represent a rapidly evolving alternative for the 
treatment of such patients. The increasing implementation of these techniques into the 
clinical routine may have a major impact on the treatment strategy of patients with valvular 
heart disease (3). Various percutaneous catheter-based as well as transapical surgical 
implantation approaches have been developed and were successfully applied in both 
settings, experimental as well as in the clinical arena, representing a promising alternative to 
conventional heart valve surgery (4-6). Despite these significant advances, the currently 
available valvular constructs for minimally invasive, transcatheter-based procedures are bio-
prosthetic and as such inherently prone to progressive degeneration and calcification 
suggesting their clinical indication primarily in the elderly, high-risk patients (7).  
 
Tissue engineering approaches aiming at the fabrication of cell based, living heart valves 
have created substantial clinical hope and expectations to overcome these limitations. 
Different concepts using various cell sources and scaffold materials have been introduced 
over the past decade. The major aim of tissue engineering technologies is to generate tissue 
constructs based on their cellular components which comprise the characteristics of their 
native counterpart. In addition to long-term durability and sufficient mechanical properties, 
the absence of immunogenic or inflammatory responses represents a key factor for a 
functional tissue engineered heart valve. This aim can be achieved with a completely 
autologous tissue engineering concept.  
 
The success of this approach depends on three key aspects: (1) a biodegradable and 
biocompatible matrix (scaffold) which determines the three-dimensional shape and serves as 
an initial guiding structure for cell attachment and tissue development; (2) an easy accessible 
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cell source from which a native-analogous living tissue can be generated; and (3) either 
sophisticated in vitro culture conditions which enable adequate neo-tissue formation resulting 
in implantable, living, autologous heart valve constructs, or in vivo concepts using directly 
implantable matrices with potential of in vivo remodeling and cell in-growth. 
 
Particularly for pediatric applications, the growth potential of tissue engineered heart valves 
addresses an unmet medical and may prevent children with congenital malformations from 
high risk redo operations. Therefore, this concept may extend the future clinical application of 
trans-catheter valves beyond elderly high-risk patients to a broader patient population, 
including young patients (8). Furthermore the combination with stem cells may further 
increase the regenerative potential of tissue-engineered constructs. In particular, marrow 
stromal derived stem cells have been repeatedly suggested to represent an ideal cell source 
for cardiovascular tissue engineering. A clinically relevant heart valve tissue engineering 
concept would ideally comprise minimally-invasive techniques for both, cell harvest and valve 
implantation. 
 
A brief overview about current state-of-the-art treatment strategies for valvular heart disease 
and its current limitation along with the principle concept of clinically relevant heart valve 
tissue engineering is provided. 
 
1.1. Valvular Heart Disease 
Valvular heart disease represents a major global disease load with an increasing number of 
patients in the developed world suffering from degenerative valve disease as well as an 
increasing patient cohort in the developing countries due to rheumatic diseases (1, 2, 9). For 
this reason it remains to be a significant cause of morbidity and mortality worldwide (10). 
More than 250,000 heart valve replacements are performed worldwide per year with a 
continuously increasing tendency that is expected to have tripled by the year 2050 (11). 
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1.2 Heart Valve Replacements 
Surgical replacement applying a mechanical or bioprosthetic prosthesis represents the most 
common therapy for end-stage valvular disease and is a safe and efficient approach. 
Although current available prostheses demonstrate excellent structural durability (9, 12-14), 
several limitations remain unsolved including the lack of growth capacity as well as the repair 
and remodeling properties after implantation into the body. In addition, mechanical valves are 
well known to have an increased risk of thromboembolic events due to a non-physiological 
flow pattern and the associated high shear stresses permanently causing erythrocyte 
damage. Next, a lifelong anticoagulation therapy is required for these patients carrying a risk 
of spontaneous bleeding and embolism (15). In contrast, bioprotheses, either originating from 
animals (xenografts) or from human donors (homografts) do not require this lifelong 
anticoagulation, but are more prone to dysfunctional, degenerative processes requiring high-
risk redo operations. Therefore these prostheses are less suitable for middle-aged and 
younger patients (16) which is also in line with the current clinical guidelines suggesting the 
use of bioprosthetic valves in patients aged > 65 years and older (12, 13). 
 
While the native heart valve consists of living tissue with the capacity to continuously adapt 
to the hemodynamic environment (17), none of the above mentioned, artificial prostheses is 
capable to fully replace the native valvular function due to the lack of these adaptive 
properties. While in theory, the use of cryopreserved donor heart valves would represent an 
ideal concept with a low risk for thromboembolic events and infection, the real clinical world 
appears to be quite different due to the shortness of these prostheses, while the number of 
indigent patients is permanently increasing (18). Summarising it can be said, these 
limitations clearly indicate that current therapy options of heart valve replacements are still 
suboptimal and the ideal concept needs to be developed (11).  
The concept of heart valve tissue engineering represents a promising field of research to 
overcome these limitations and has created substantial hope as well as expectations. The 
idea of generating a living autologous valve that is not associated with any immune reaction, 
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thromboembolic events as well as degeneration processes, while offering the potential of 
growth and remodeling may represent an ideal next generation therapy concept for heart 
valve replacements. 
 
1.3 The Evolution of Transcatheter Valves 
The therapy for valvular heart disease is currently undergoing rapid changes and in addition 
to conventional valve replacement representing the gold standard since several decades, 
transcatheter techniques have been introduced into the clinical arena for the treatment of 
elderly high-risk patients. Current data demonstrate satisfactory hospital outcomes and mid-
term results.  
While the conventional approach provides very precise and safe suturing of standard valves 
with low failure rates and excellent proven long-term outcomes (9, 12-14), transcatheter 
techniques can be performed in off-pump beating-heart fashion that can even be performed 
without general anesthesia in selected patients. Its long-term safety proven via clinical, 
randomized trials, it can be assumed that the indications for this minimally invasive 
procedure will be continuously extended towards younger and less riskful candidates.  
Driven by the idea of implanting stented valves into the aortic annulus in the 1990s, the first-
in-man transcatheter aortic stent-valve implantation was performed by Dr. Cribier in Rouen, 
France (19) in the beginning of 2002. Two specific routes for implantation have been 
established since then: the antegrade way via a surgical, direct transapical access, and the 
retrograde way using a transfemoral catheter-based concept (20, 21). The transapical 
approach requires a left anterolateral mini-thoracotomy followed by a pledged purse-string 
suture to enter the apex, whereas the transfemoral method requires an adequate peripheral 
vascular access and can be performed fully percutaneously (figure 1). 
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Figure 1: The concept of transcatheter heart valve implantation: Transcatheter valves can either 
be implanted via a retrograde, transfemoral approach (A) or via an antegrade transapical approach 
(B). 
 
 
The main advantage of the transapical technique is the independence from concomitant 
peripheral vascular disease or previous aortic surgery. Furthermore, the delivery system 
appears to be more “steady” and the procedure itself more “straightforward” and this access 
potentially reduces the risk of calcium embolism which may occur when a stiff trans-femoral 
device passes from a peripheral vessel into a diseased aortic arch. The major benefit of the 
transfemoral approach is the feasibility of a fully percutaneous implantation in conscious 
patients. However, this only applies to patients with absence of peripheral artery disease and 
an adequate caliber (>6 mm diameter) of their peripheral vessels not being very tortuous. 
With regards to the current international guidelines, the presence of peripheral vascular 
disease, small vessel diameters, tortuous vessels, aortic disease or previous aortic surgery 
represent the major contraindications for this approach. 
 
Since this breakthrough of the transcatheter technique in 2002, two different suture-less 
transcatheter aortic stent valves have been developed and were successfully introduced into 
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the current clinical routine: the Edwards Sapien™ THV stent-valve system by Edwards 
Lifesciences INC, Irvine, CA, which is available for both the antegrade and the retrograde 
applications and the CoreValve® system by Medtronic, Minneapolis, MN, which is only 
available for a retrograde approach. In addition, several other devices are under clinical 
investigation. 
 
1.4 The Concept of Tissue Engineering 
The principle idea of the tissue engineering is the generation of autologous living tissues 
being equal in architecture and function to their native counterparts. Therefore, a meticulous 
understanding of the fundamental characteristics of native tissue represents the key factor 
for the successful generation of native analogous tissue-engineered constructs. In the field of 
cardiovascular medicine, the in vitro generation of heart valves represents an example of 
how tissue engineering approaches aim to solve the limitations of current clinical therapy 
options. Composed of living, dynamic tissue capable of continuous remodeling, native heart 
valves are permanently adapting to the constantly alternating hemodynamic situation in the 
circulation (17), while none of the currently available valvular replacement prostheses are 
capable to fully restore the native function due to the limited long-term adaptive capacity (22). 
The currently available state-of-the-art prostheses in today's clinical routine are well 
established to show considerable limitations. In particular, these include limited remodeling 
capabilities and the lack of growth capacity, a major drawback in the setting of congenital 
applications. In addition, mechanical heart valves are well established to carry an increased 
risk of thromboembolic events due to high shear stress, nonphysiological flow patterns, and 
permanent blood damage requiring a lifelong anticoagulation therapy (23), (e.g. warfarin), 
which is associated with a significant risk of haemorrhagic complications, and 
thromboembolic incidences.  Additional problems may occur in young fertile females when 
considering the embryo toxicity of warfarin or similar substances. While bioprostheses from 
xenogenic or homogenic origin do not require anticoagulation, they represent non-viable 
prostheses prone to degeneration. For this reason, the need for a high-risk re-replacement 
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normally occurs within 10–15 years and even faster in younger patients due to a higher 
immunological competence (11, 16). 
Tissue engineering technologies may potentially overcome these limitations by creating a 
living autologous valve replacement that may prevent from an immune reaction, valvular 
degeneration and thromboembolic events, while offering the significant advantages of growth 
capacity, remodeling, and regeneration throughout the patient's lifetime. The central dogma 
of most tissue engineering concepts is the use of temporary, biodegradable supporter 
matrices in order to support tissue functionality and stability during the engineering process 
until a sufficient amount of neo-tissue is produced to achieve an adequate physiological 
function (22). After this in vitro phase, the generated living tissue is implanted into the patient 
aiming at a further in vivo remodeling process to achieve a sufficient cardiac vascular 
architecture and function. Significantly influencing the fate of the generated substitute, this in 
vivo remodeling phase represents a decisive step of a successful engineering concept. 
 
1.5 Strategies in tissue engineering: in vitro or in vivo 
Two major tissue engineering strategies have been established to generate living autologous 
constructs: The in vitro and the in vivo concept. Being the classical approach, the first 
concept requires a sufficient in-vitro period to generate the ideal native-like construct (22). 
Briefly, it starts with the isolation and expansion of cells from the patient, followed by the 
subsequent seeding onto a scaffold material, a defined bio-reactor phase for sufficient in vitro  
tissue formation and is completed by the final implantation into the patient. This concept, 
representing the principal approach for heart valve tissue engineering, aims at the complete 
in vitro generation of the tissue engineered substitute. 
In contrast, the second, alternative in vivo approach of heart valve tissue engineering avoids 
this in vitro  tissue culturing period by direct implantation of natural tissue-derived heart valve 
scaffolds with the idea of potential remodeling and cell in-growth in vivo (24). More recently, 
and due to the significant advances in the field of stem cell technology, a further in vivo 
concept has been suggested: Based on the idea of chemo-attractive paracrine pathways, the 
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seeding of the substitute with autologous stem cells including progenitor and/or mononuclear 
cells, may lead to the attraction of endogenous cells supporting the remodeling process and 
the formation of novel tissue (25). 
 
Figure 2: Concept of cardiovascular tissue engineering: Autologous cells are harvested from the 
patient and expanded in vitro. When sufficient numbers are reached, cells are seeded onto a 
biodegradable scaffold. Constructs are either positioned in a bioreactor and conditioned (in vitro 
approach) or directly implanted into the patient (in vivo approach). After implantation of the tissue-
engineered construct, the proposed mechanism of vascular remodeling comprises an early monocyte 
recruitment to the scaffold with the release of multiple angiogenic cytokines and growth factors. These 
factors (i.e., VEGF) cause recruitment of host cells, such as MC, SMCs, and ECs, to the scaffold. The 
invading host cells originate from circulating progenitors and (trans-anastomotic) migration/in-growth 
of mature vascular cells from adjacent vessel segments. Incoming ECs and SMCs appropriately 
organize into a mature blood vessel structure on the luminal surface of the scaffold (with the remaining 
scaffold in the center of the construct). As the scaffold degrades, early monocytes migrate away, 
leaving behind a remodelled, completely autologous neo-vessel (Weber, Emmert et al; Review; Semin 
Immunopathol. 2011). 
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1.6 Pediatric Implications and the concept of growth 
Approximately one out of hundred newborns presents with congenital heart defects often 
requiring the implantation of prosthetic or homograft constructs including heart valve 
replacements. The current available prostheses are non-viable substitutes lacking the 
capacity of growth as well as, repair and remodeling properties. Therefore, a lot of these 
affected children often require complex and high-risk redo surgery (26). 
 
Based on these disadvantages, alternative strategies remain to be developed. The concept 
of tissue engineering addressing the fundamental need for growing constructs may represent 
a promising, next generation approach for future congenital therapy concepts. In the last 
decade, extensive research has proven the feasibility of autologous tissue engineering 
concepts for cardiovascular applications such as heart valves (27-29) and blood vessels 
(30). 
 
Tissue-engineered grafts were successfully applied to the low (31) as well as to the systemic 
pressure system (32) in animal models and the translation into a clinical setting using human 
cells has also been demonstrated (27, 33). The group of Shin’oka and colleagues (34) were 
the first entering the clinical arena and recently reported initial clinical results on vascular 
autografts generated from human bone marrow cells (35, 36). Following this breakthrough, 
the field was further pioneered by Hoerstrup and associates who systematically 
demonstrated the concept of growth in tissue engineered cardiovascular constructs using a 
long-term, growing animal model. Hoerstrup et al. recently investigated the potential of 
growth in tissue-engineered living main pulmonary arteries over a period of 100 weeks in a 
lamb, covering the full growth of this animal model (26). 
 
The animals more than doubled their body weight during the 100 weeks follow up period and 
concomitantly, there was a significant increase of the mean diameter (30%) and lengths 
(45%) of the TEVGs in parallel to the native pulmonary arteries indicating sufficient growth 
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with the animals. Sufficient functionality was demonstrated by regular echocardiography and 
computed tomography–angiography up to 100 weeks post implantation. In particular, there 
were no signs of malfunction or degeneration including thrombus formation, calcification, 
stenosis, suture dehiscence, or aneurysm formation. Next, histology displayed tissue 
formation reminiscent of the native artery and biochemical analysis revealed cellularity and 
proteoglycans and increased collagen contents in all of the groups, analogous to those of 
native vessels (26).  
 
The authors defined this capacity of tissue remodeling and adaptation to the growing 
cardiovascular system - initiated by in vitro generated tissue engineered vascular grafts – as 
guided tissue regeneration leading to functional growth. Furthermore, they concluded that 
this study provides systematic evidence of the capacity of growth in living, functional 
pulmonary arteries engineered from vascular cells in a full growth animal model highlighting 
the huge potential of tissue-engineering concepts for congenital applications. 
 
Based on these data and as a next step, selected animals were followed up for up to 5 years. 
At this point, the initial results could be confirmed with the help of high-resolution computed 
tomography using a unique 3D CT reconstruction analysis which displayed sufficient and 
stable wall pressure, shear stress, and flow velocity, in the tissue engineered graft during 
systole and diastole over the whole follow-up period. In detail, the 3D CT analysis displayed 
a smooth flow pattern and low wall pressure during systole at all times for up to 240 weeks. 
The low wall shear stress and the absence of turbulences indicated native analogous 
vascular performance and absence of degenerative phenomena, such as atherosclerotic 
calcifications. Moreover, continuous functional growth was confirmed by CT volume 
measurements, revealing a significant volume increase of the tissue engineered graft starting 
from an initial volume of 6 ccm 20 weeks after implantation up to 13 ccm after 240 weeks 
(Emmert & Hoerstrup et al.; unpublished data). 
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Figure 3: Three dimensional CT reconstruction analysis of wall pressure, shear stress, and 
flow velocity in the pulmonary-trunc for up to 4.5 years post implantation: Calculated wall 
pressure (Pa), wall shear stress (WSS) (Pa) and velocity-coded streamlines (m/s) in the pulmonary 
trunc during systoly and diastoly of three different sheep, 50, 100 and 240 weeks after implantation of 
the tissue engineered graft. The flow pattern remains to be smooth with low wall shear stress during 
the systole in all three sheep, especially after 240 weeks, although the pressure is slightly higher. The 
low shear stress and the absence of turbulences indicate that no significant wall irregularities, as e.g. 
atherosclerosis, aneurysms or scars, are present (Emmert & Hoerstrup et al.; unpublished data). 
 
As it has been reported that follow-up periods in a lamb model can be extrapolated to a four- 
to fivefold period of time in humans (37), these results represent approx. 20 years in a 
human demonstrating a first example as to the potential long-term clinical safety of 
autologous tissue engineering technologies. 
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1.7 Cell Sources 
The selection of the ideal cell type is an important aspect for the long-term success of heart 
valve tissue engineering (17, 38) and currently different cell sources are under evaluation 
(22, 29, 38-40). 
 
1.7.1 Vascular cells 
The use of vascular cells derived from various saphenous and arterial vessels is an 
established approach for heart valve tissue engineering (38).In brief, two cell types can be 
isolated: Endothelial cells (ECs) with antithrombogenic properties and myofibroblasts which 
are capable to develop extracellular matrix (ECM) (41-43). Following preliminary data in 
sheep (15, 28, 41-44), human vascular-derived cells revealed sufficient tissue formation after 
seeding on biodegradable scaffolds (38, 45-47).  
 
1.7.2 Marrow stromal derived stem cells 
With regards to clinically relevant tissue engineering concepts, marrow stromal cells (MSCs) 
may represent an ideal cell source with regards to availability, safety and regenerative 
potential (15, 27, 48). MSCs were successfully used for the in vitro production of heart valves 
(27, 48), and also demonstrated sufficient in vivo functionality (49). When compared to 
vascular cells, these cells can be harvested without the necessity of surgical interventions 
and can be considered as an easy-to-access cell source. In brief, the usage of MSCs offers 
several advantages in a) easy harvest by a simple bone marrow puncture (hip puncture or 
sternal puncture); b) high regenerative potential due to the capacity to differentiate into 
multiple cell lineages, and c) advantageous immunological characteristics allowing for 
clinically relevant allogenic scenarios. 
 
1.7.3 Endothelial progenitor cells (EPCs) 
Endothelial progenitor cells can easily be isolated from peripheral blood (50) and have been 
established as source of ECs (50, 51). While representing an easily accessible cell source, 
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the current focus of research aims at their potential to trans-differentiate into myofibroblast-
like cells. Its potential proven, the blood may represent an interesting cell source for heart 
valve tissue (22). 
 
1.7.4 Umbilical cord derived Cells 
The umbilical cord represents a valuable source of different cell types that can be used for 
heart valve tissue engineering: (1) umbilical cord vein-derived and artery-derived cells, (2) 
Wharton's Jelly-derived MSCs, and (3) umbilical cord blood-derived EPCs. These cells have 
been repeatedly demonstrated a high regenerative potential, excellent tissue formation and 
growth capacities (39, 52-54). The feasibility using umbilical cord derived stem cells to 
generate different cardiovascular constructs was recently demonstrated (39, 40) suggesting 
this cell source to be clinically relevant. 
 
1.7.5 Adipose Tissue derived mesenchymal stem cells 
Similar to the bone marrow, the adipose tissue also contains mesenchymal stem cells with 
the potential to differentiate into multiple lineages in vitro (55, 56) and in vivo (57, 58). 
However, due to the easy access and the high availability, adipose-derived stem cells are 
likely to represent an alternative stem cell source when compared to MSCs derived from the 
bone marrow (59). 
 
1.7.6 Prenatal Progenitor Cells 
When focussing on pediatric tissue engineering, an ideal concept would comprise an 
prenatal fetal cell harvest giving the opportunity for tissue engineering processes during 
pregnancy followed by the implantation instantly after birth (22). Based on this concept, 
Schmidt et al. successfully generated autologous heart valve leaflets using human prenatal 
progenitor cells derived from chorionic villi and umbilical cord blood (54). Additionally, the 
fabrication of living autologous heart valves prior to birth using human amniotic fluid-derived 
cells could be demonstrated (60, 61). 
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Figure 4: Cell Sources for Cardiovascular Tissue Engineering Standard vascular endothelial cells 
(SVECs), Endothelial progenitor cells (EPCs), Bone marrow-derived mesenchymal stem cells 
(BMSCs), Adipose-derived stem cells (ADSCs), Umbilical cord-derived progenitor cells (UCDPCs), 
Chorionic villi-derived mesenchymal progenitor cells (CVMPCs), Amniotic fluid-derived progenitor cells 
(AFDPCs), Embryonic stem cells (ESCs), Adult spermatogonial stem cells (ASSCs) and Induced 
pluripotent stem cells (IPSCs). (B) Concept of in vitro heart valve tissue engineering. Autologous 
cells are harvested from the patient and expanded in vitro (1). When sufficient numbers are reached, 
cells are seeded onto a biodegradable scaffold (2). Constructs are positioned in a bioreactor (3) and 
conditioned. When tissue formation is sufficient, tissue engineered heart valves (4) are ready for 
implantation (5) (Weber & Hoerstrup; Bookchapter; Regenerating Heart Valves; Springer 2011). 
 
1.8 Starter matrices for cardiovascular tissue engineering 
The development of biocompatible starter matrices and scaffolds for heart valve tissue 
engineering comprises of two main routes: (a) biological matrix materials and (b) a fully 
synthetic scaffold (22, 62). 
 
In principal, the design of a scaffold should be adapted to the native counterpart as exactly 
as possible. Next, it should support cellular growth including cell-to-cell interaction and neo-
tissue formation displaying an organ specific extracellular matrix. Furthermore, it should be 
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capable to cope with the mechanically complex cardiovascular environment. These 
mentioned key aspects are crucial for the success of the tissue-engineered constitutes, 
regardless of the material of the scaffold or the matrix.  
 
The surfaces of these starter matrices must provide sufficient biocompatibility including a 
significant potential of cellular in-growth, as well as an optimized degradation rate for cellular 
expansion (63). Based on these specific requirements, numerous concepts to identify the 
ideal scaffold material have been developed and are currently under investigation including 
the creation of biological (64) and synthetic scaffold materials (65) which can further be 
subdivided into subgroups (22): these include native tissue-derived ECM scaffolds (66), 
polymeric scaffolds (67-70), biological-polymeric hybrid scaffolds (71-73), and collagen or 
fibrin gel scaffolds (74-77).  
 
Although significant advances have been made in all of these concepts, the application of 
polymeric scaffolds has turned out to be the most interesting approach in the field of heart 
valve tissue engineering approaches. 
In general, the application of polymeric scaffolds for different tissue engineering strategies 
has already been extensively elucidated (65). With regard to state-of-the-art tissue 
engineering an ideal scaffold matrix has to be at least 90% porous (78) which is essential for 
cell growth and nutrient supply. Additionally, the scaffold material should also meet the 
mechanical criteria of a native heart valve and should display a cell-favourable surface 
chemistry (65). Next, the degradation rate of the matrix should be controllable and adaptable 
to the rate of neo-tissue formation (17, 79). Table 1 summarizes a compilation of different 
synthetic polymers which are under evaluation as potential starter matrices in the field of 
heart valve tissue engineering. 
 
As one concept, the family of aliphatic polyesters including polyglycolic acid (PGA), 
polyglactin (PG), and polylactic acid (PLA) has been used to create single heart valve 
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leaflets. However, the major limitations of these aliphatic polyesters - when used as sole 
material - are their initial stiffness, thickness, and non-pliability making it complicated to 
generate complete tri-leaflet heart valves (22). 
 
In another concept, polyhydroxyalcanoate (PHA) and poly-4-hydroxybutyrate have been 
used to generate tri-leaflet heart valve conduits (47, 80) and while these materials Are easily 
transferable to any desired shape (81) and provide excellent thermoplastic properties, their 
low degradation rate can be considered as a major limitation. 
 
Furthermore, the combination of aliphatic polyesters and PHAs has been applied as a 
potential alternative (28, 82) and particularly the approach with P4HB coated PGA may be 
efficient. Combining the thermoplastic properties of P4HB and the excellent porosity of PGA 
seems to be a promising approach for the fabrication of tissue engineered heart valves (27, 
28, 61, 82-84). 
 
Table 1: Examples of polymeric starter matrices used for cardiovascular tissue engineering 
(Weber, Emmert et al; Review; Semin Immunopathol. 2011); PGA polyglycolic acid; PHA 
polyhydroxyalkanoate; PHO polyhydroxyoctanoate; PEUU poly(ester–urethane)urea; PEEUU 
poly(ether–ester–urethane)urea; PLLA polylactic acid; P4HB poly-4-hydroxybutyrate; TEHV tissue-
engineered heart valve  
 
1.9 The implant-mediated inflammatory response: the key to tissue remodeling? 
The idea of in vivo healing of tissue-engineered constructs can be considered as a 
continuous, multi-factorial process. After the initial blood-material interactions this cascade 
consists of an initial acute inflammation which is then followed by several repair processes 
(figure 5): In brief, immediately after implantation, phagocytic cells originating from the 
microcirculation (such as neutrophiles and monocytes which appear to play a key role in the 
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healing and remodeling process) enter the interface between the implant surface and the 
injured native tissue. The period of acute inflammation (up to several weeks in humans) 
includes the initial phagocytic removal of debris due to trauma, which is then followed by a 
phase of appropriate signalling to shift from inflammation to repair, regeneration and 
remodeling of the tissue (22). Mendelson and colleagues have recently suggested that the 
success of in vivo remodeling of tissue-engineered substitutes is decisively influenced by two 
main processes: (A) The formation of an atypical vascular response to injury at the luminal 
surface, including intimal thickening, pannus formation, and neointima development, and (B) 
deep tissue biomaterial-associated effects of foreign body reaction, granulation, tissue 
formation, and fibrosis forming a media-like structure (85).  
 
On the cellular level, monocytes appear to play a crucial role in the different steps of the 
healing cascade. After the initial phase of acute inflammation, they are detectable in the 
implanted construct. It has also been reported that the monocyte chemotactic protein (MCP-
1), a potent monocyte-attracting cytokine, is released by activated neutrophils at the site of 
implantation indicating to represent a key factor within the early remodeling period, which is 
mainly characterized by chemotactic immune cell infiltration (86).  
 
Next, monocytes seem to play an important role in the entire remodeling process as they 
remain in the implanted scaffold until it has fully degraded (22). A recent study of Hoerstrup 
et al. demonstrated a heterogeneous mononuclear inflammation in the areas of residual 
polymer fibers for up to two years after implantation of a tissue-engineered graft (26). 
Moreover, monocytes produce a wide range of cytokines (i.e., MCP-1/CCL-2, IL-6, IP-10), 
growth factors, and proteases which are required for vascular cell proliferation/migration and 
appropriate vascular remodeling (85, 87, 88). Furthermore, they express extracellular matrix 
remodeling proteases (i.e., MMPs), cytokines characteristic of the innate immune response 
(IL-1α, IL-1β, IL-6, IL-10, and TNFα) and cell adhesion (ICAM-1, VCAM-1) (22). 
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Apart from the decisive role of MCP-1 for monocytic attraction and despite a successful 
proof-of-concept study attaching MCP-1-releasing biodegradable microparticles to the 
scaffold matrix in order to mimic the chemo-attractive properties of seeded cells in vivo, the 
exact pathways explaining these remodeling mechanisms remain unclear. However, for the 
development of strategies to modulate early inflammatory responses and to increase tissue 
remodeling, the complete understanding of these underlying cascade is crucial and has to be 
elucidated (22, 89). 
 
 
 
 
 
Figure 5: The concept of remodeling and functional healing response: Schematic diagram 
depicting the concept of remodeling and functional healing response in a tissue engineered graft 
model: After implantation of a tissue engineered vascular graft (TEVG), a functional healing response 
occurs (0-20weeks), which is accompanied by a transient inflammatory response, cellular in-growth 
and repopulation of endogenous cells into the TEVG. A pannus containing a-SMA and desmin cells 
has formed at the luminal surface (neo-intima) and granulation tissue evolving into fibrous tissue 
containing glycosaminoglycans and collagen. These cells originate from different sources and 
approach the TEVG via different mechanisms including the trans-anastomotic in-growth (i), blood 
derived cell immigration (ii), or adventitia derived cell migration (iii). Whereas the interface between the 
TEVG and the native vessel is still detectable within the period of 20-100 weeks it is equalized after a 
100 weeks and fully integrated and indistinguishable after 240 weeks in vivo indicating completion of 
tissue remodeling beyond 100 weeks (Emmert & Hoerstrup et al; unpublished concept figure). 
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1.10 Aim of Habilitation Thesis 
This habilitation thesis summarizes the systematic development of translational, clinically 
relevant tissue engineered heart valve concepts by combining the use of sophisticated stem 
cell approaches, state-of-the-art tissue engineering protocols and minimally invasive valve 
implantation techniques. 
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2. Summary of Publications  
(full publications are available in the appendix, page 62) 
 
2.1 Minimally-Invasive Implantation of Living Tissue Engineered Heart 
Valves - A Comprehensive Approach from Autologous Vascular Cells to Stem 
Cells 
Schmidt D, Dijkman PE, Driessen-Mol A, Stenger R, Mariani C, Puolakka A, Rissanen M, 
Deichmann T, Odermatt B, Weber B, Emmert MY, Zund G, Baaijens FP, Hoerstrup SP 
Journal Am Coll Cardiol. 2010 Aug 3;56(6):510-20. 
 
In this article, for the first time, the principal feasibility of merging tissue engineering and 
minimally-invasive valve implantation techniques using vascular cells and adult stem cells 
was successfully demonstrated. 
 
While the feasibility and functionality of tissue engineered heart valves (TEHVs) implanted by 
conventional surgical procedures have been demonstrated by in vivo experiments and initial 
clinical trials (27-29, 55, 65, 84), a clinically relevant heart valve tissue engineering concept 
would ideally comprise both, minimally-invasive techniques for cell harvest and valve 
implantation. Therefore, the aim of this study was to demonstrate the feasibility of combining 
the novel heart valve replacement technologies of: 1) tissue engineering; and 2) minimally-
invasive implantation techniques based on autologous cells and composite self-expandable 
biodegradable biomaterials. 
 
Tri-leaflet heart valves fabricated from biodegradable synthetic scaffolds, integrated in self-
expanding stents and seeded with autologous vascular or stem cells (bone marrow and 
peripheral blood), were generated in vitro using dynamic bioreactors. Subsequently, the 
tissue engineered heart valves (TEHV) were minimally-invasively implanted as pulmonary 
valve replacements in juvenile sheep. In addition to the in vivo functionality assessed by 
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echocardiography and angiography up to 8 weeks, the tissue composition of explanted 
TEHV and corresponding control valves was evaluated. 
 
The implantation procedure was uneventful in all animals with regards to perioperative 
morbidity or mortality. Confirmed by fluoroscopy, all valves were deployed successfully at the 
targeted site and no migration of the TEHV or paravalvular leakage was observed. 
Transthoracic echocardiographic demonstrated sufficient valvular function and revealed an 
initial mean pressure gradient of 30 mm Hg which was constantly decreasing to 10 mm Hg. 
Two study animals displayed minimal regurgitation which remained unchanged over the 
whole period of implantation time. Histology revealed layered neo-tissues with 
endothelialized surfaces. Quantitative extracellular matrix analysis at 8 weeks showed higher 
values for deoxyribonucleic acid, collagen, and glycosaminoglycans compared to native 
valves. Mechanical profiles demonstrated sufficient tissue strength, but less pliability 
independent of the cell source after 4 weeks in vivo. 
 
For the first time and in a translational, clinically relevant setting, the principal feasibility of 
combining stem-cell based, autologous tissue engineering concepts and minimally-invasive 
valve replacement techniques was demonstrated. 
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2.2 Tissue engineered vascular graft remodeling in a growing lamb model: 
expression of matrix metalloproteinases 
Cummings I, George S, Kelm J, Schmidt D, Emmert MY, Weber B, Falk V, Zünd G, 
Hoerstrup SP 
Eur J Cardiothorac Surg. 2011 Apr 27. [Epub ahead of print] 
 
As future clinical applications of tissue engineering require a meticulous understanding of the 
underlying mechanisms of neo-tissue formation and matrix remodeling, in this article the 
specific role of matrix metalloproteinases (MMP) with regards to matrix remodeling, tissue 
homeostasis and functional growth was investigated.  
 
Matrix metalloproteinases (MMPs) are zinc-dependent peptidases broadly classified 
according to their substrate-degradation capabilities and were found to contribute to 
extracellular matrix remodeling more than fifty years ago. Additionally, MMP-related 
processes are expected to play a key role in tissue homeostasis and functional growth. 
Synthesized in the latent form as Zymogens, they are secreted as pro-enzymes (pro-MMPs), 
before they are activated via a process known as the cysteine-Zn+ switch which enables 
proteolytic activity (90, 91). In summary, smooth muscle cells produce pro-MMP-2 in the wall 
of normal arterial walls and in culture, while active MMP-2 and pro- and active MMP-9 are 
absent. In contrast, diseased vessels undergoing remodeling processes generate active 
MMP-2 and MMP-9 (92-95). Therefore the focus was on the expression of the gelatinases 
MMP-2 and-9. MMP-2 has been demonstrated to degrade native type IV, V, VI, and X 
collagen as well as denatured collagen, proteoglycans, elastin, and growth factors. MMP-9 
degrades gelatin, an irreversibly hydrolyzed collagen, and is expressed following injury or 
inflammatory stimulation (96).  
 
Using a previously published growing lamb animal model elucidating the concept of growth 
(26), tissue-engineered autologous living pulmonary arteries were analyzed as to MMP 
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profiles including MMP-2 and -9 expression as well as microstructure and tissue composition, 
and were compared with native arterial tissue. Briefly, these tissue engineered vascular 
grafts generated from biodegradable scaffolds seeded with autologous vascular cells were 
cultured in static and dynamic in vitro conditions. Thereafter, they were implanted as 
pulmonary artery replacements in lambs and followed up for 2 years.  
Gelatin gel zymography to detect MMP-2 and -9 was done and collagen content 
quantification was performed. Latent (pro) and active MMP-2 and -9 were detected. 
Comparable levels of active MMP-9 and pro-MMP-2 were identified in both, static and 
dynamic cultures, while higher levels of active MMP-2 were detected in dynamic cultures. 
Whereas the expression of MMP-2 and -9 was very low in native grafts, it but was increased 
in the implanted tissue engineered vascular grafts. Pro-MMP-9 was expressed 20 weeks 
after implantation persisting up to 80 weeks post implantation. The in vitro analysis revealed 
increased levels of collagen after dynamically conditioned tissue engineered grafts when 
compared to their statically conditioned counterparts. Next, the collagen content of the 
engineered gtrafts was also higher when compared to the native vessel. Based on these 
results, it was concluded that MMPs are up-regulated in vitro by dynamic culture conditions 
and may contribute to enhanced matrix remodeling, native analogous tissue formation and 
functional growth of tissue engineered grafts in vivo.  
 
Furthermore, the presence of elevated MMP activity even in the long-term grafts suggests a 
sustained remodeling activity maintaining functionality and homeostasis of the tissue. Based 
on a more meticulous understanding of matrix remodeling, state-of-the-art imaging modalities 
may support non-invasive tracking of MMP activity in clinical settings to define clinically 
relevant tissue quality criteria that may contribute to the safe translation of tissue-engineering 
technologies to the clinical arena (97). Next, a more detailed insight into the remodeling 
pathways involving MMPs may support the specific production of design intelligent scaffold 
materials supporting remodeling phenomena within tissue-engineered constructs by 
attaching transcription factors and/or cytokines to the starter matrices. 
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2.3 Injectable living marrow stromal cell-based autologous tissue 
engineered heart valves: first experiences with a one-step intervention in 
primates 
Emmert MY*, Weber B*, Scherman J*, Gruenenfelder J, Verbeek R, Bracher M, Black M, 
Kortsmit J, Franz T, Schoenauer R,  Baumgartner L, Brokopp C, Agarkova I, Wolint P, Zund 
G, Falk, Zilla P, Hoerstrup SP. 
Eur Heart J. 2011 Mar 17. [Epub ahead of print]; *contributed equally 
 
Following the demonstrated feasibility of merging in-vitro tissue engineering concepts with 
minimally invasive implantation techniques (49) and based on the principle idea of an in vivo 
remodeling approach, the aim of this study concept was an even more clinically relevant 
setting. Using a non-human primate model being well comparable to humans, the fabrication 
of marrow stromal cell-based, autologous, living tissue engineered heart valves (TEHVs) and 
direct minimally invasive implantation in the same intervention (one step procedure) as 
pulmonary valve replacements was tested (figure 6).  
Trileaflet heart valve scaffolds were generated andintegrated into self-expandable nitinol 
stents. Bone marrow was aspirated from the sternum of adult Chacma Baboons and 
mononuclear cells were obtained by centrifuging the samples on a histopaque density 
gradient seeding of the BMCs onto the stented heart valve scaffolds (8+3 ×106 cells/cm2). 
This was performed using fibrin as a cell carrier. The isolation of BMCs revealed 175+82 × 
106 cells per animal for seeding, while cellular viability was in excess of 95%. Isolated 
primate mononuclear cells stained positively for common leucocytic antigens including CD45, 
CD44, and CD15 and flow cytometric analysis of the marrow mononuclear cells comprised 
distinct leucocytic cell populations. Primate bone marrow aspirate contained CD34+ 
haematopoietic stem cells as well as mesenchymal stem cells staining positive for CD44, 
CD90, CD146, and CD166, while being negative for CD45 and CD34, representing a 
common staining pattern for MSCs. The differentiation potential of isolated primate MSCs 
was confirmed exemplarily using pre-adipocytic and osteoblastic differentiation assays. 
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The transapical implantation procedure was successful in all animals and in five out of six 
cases the valves were optimally deployed in the orthotopic valvular position, whereas one 
valve was positioned supravalvularly thereby not excluding the native valvular leaflets. One 
study animal with an orthotopically implanted valve suffered perioperatively from coronary 
perfusion complications which were not related to the TEHV functionality and was terminated 
12 hours post implantation. The positioning of the TEHV was confirmed intra-operatively 
using TEE and fluoroscopy. Importantly, neither migration of the TEHV nor paravalvular 
leakage was observed, while sufficient valve functionality was demonstrated. The mean 
crimping time of the TEHV, from insertion into the application system until surgical 
deployment, was 17+8 min and the mean duration of the entire procedure, from bone marrow 
harvest until valve delivery, was 118+17 min. 
 
 
Figure 6: Concept of One-Step Procedure for Minimally invasive tissue engineered heart valve 
implantation: After sternal bone marrow puncture (A) and aspiration of fluid (B), the tissue 
engineered heart valve was loaded into the delivery device (C), inserted into the right ventricle (D) and 
deployed in the pulmonary position under sonographic and fluoroscopic guidance. The crimped tissue 
engineered heart valve (a), integrated into the nitinol stent (b), was carefully deployed into the 
pulmonary position (c) by slowly advancing the inner pusher (d) into the sheath system (e). 
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While sufficient valve functionality and absence of any paravalvular leakage could be 
demonstrated throughout the follow-up period (4 weeks), weekly TTE / TEE controls 
displayed a slight but not significant increase in transvalvular peak pressure starting around 
25+ 7 mmHg (TEE) perioperatively, up to 30+7 mmHg after 3 weeks (TTE). The harvest of 
the early TEHV (12 h) displayed an intact leaflet structure dominated by a fibrin-coated PGA 
scaffold matrix without any sign of thrombus formation. The explantation of the remaining 
TEHV 4 weeks post implantation showed constructs that were well integrated into the 
adjacent tissue-by-tissue covering the stent margin and encircling stent strut endings. The 
valvular leaflets of the four orthotopically positioned constructs presented as pliable, well-
defined cusps and although the leaflets seemed to be shortened in radial diameter, sufficient 
co-aptation could be confirmed throughout the entire experimental period (figure 7). 
Interestingly, in the haemodynamically non-fully loaded TEHV deployed in the supravalvular 
position the leaflet structure was almost entirely missing. 
 
 
Figure 7: Explant analysis of tissue engineered heart valves. After 4 weeks in vivo the stented 
constructs were well integrated into the adjacent tissue (A). Orthotopical tissue engineered heart 
valves (B) presented with a cusp-like leaflet structure, with shorter leaflets than native controls. In a 
final transoesophageal echocardiography-assessment the leaflet co-aptation (C; asterisk indicates 
leaflets) as well as opening movements of all three leaflets could be visualized (D–G). 
 
 
Scanning electron microscopy displayed that the surface of the early explants (12 h) was 
mainly characterized by previously seeded mononuclear cells embedded into a fibrin matrix 
densely covering the entire scaffold. Analysis of the 4-week explants revealed that three of 
the orthotopically implanted leaflets showed already a mature structure, characterized by a 
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well-defined endothelial lining on the conduit wall as well as partially on the valvular leaflets. 
In several spots these endothelial coverages were confluent and not distinguishable from 
native primate or human valvular endothelium. 
Next, the Haematoxylin–eosin staining of the explants demonstrated layered tissue 
morphology, characterized by a central core of non-degraded PGA matrix surrounded by 
dense tissue formation on the luminal as well as on the vascular side. Masson’s Trichrome 
and eVG staining confirmed the presence of collagen predominantly in the outer layers of the 
conduit wall and the leaflet (figure 8). 
 
Figure 8: Histology of the explanted living tissue engineered heart valves. Explanted tissues 
showed layered tissue architecture visualized by haematoxylin–eosin staining (A–D). In Masson’s 
Trichrome staining (E–H) and Elastin-van-Gieson staining (I–L) collagen fibres were predominantly 
found in the outer tissue layer of the conduit and leaflets. Cells of the conduit (O) and leaflet (P) 
surface layer expressed CD31 (M–P). a-SMA expression (Q–T) was detected in the outer layers of the 
conduit (S) and the leaflet (T ), but was missing in the proximal leaflet region. Arrows indicate 
reminiscent scaffold material. 
 
 
As confirmed by SEM, the surface of the conduit was covered by a confluent endothelial 
layer in large areas of the constructs (figure 9). Cells of the constructs’ surface layer 
expressed CD31 and vWF, resembling the staining pattern of native valve endothelial cells. 
The early (12 h) as well as the late (4 weeks) explants stained positively for CD68, indicating 
a distinct monocytic infiltration and continuous remodeling. Cell tracking analysis using 
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CFSE-dye and confocal microscopy revealed no signal within the explanted tissue, indicating 
that most of the seeded BMCs were not present after 4 weeks in vivo. 
 
Figure 9: Scanning electron microscopy of the polyglycolic acid–poly-4-hydroxybutyrate scaffold (A 
and B), primate (C), and human (D) control leaflets. In most areas the surface of the 4 week explants 
showed confluent (E and F ) or initial (G) endothelial coverage. In some areas the surface remodeling 
was still evident involving thrombocyte attachment (H) and leucocyte attraction (I). 
 
Quantitative extracellular matrix (ECM) analysis of the TEHV explants showed that the GAG 
as well as the DNA content of the constructs’ leaflets was higher compared with native tissue 
(GAG 140.28+36.17%; DNA 168.10+87.07%), indicating high cellular infiltration as well as 
ECM remodeling. 
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Based on these results, the study showed for the first time the feasibility of merging heart 
valve tissue engineering using a low-invasive stem cell source, with a minimally invasive 
implantation technology combined in a single intervention. Autologous bone marrow derived 
mononuclear cells can be isolated in sufficient numbers either from the sternum or the hip 
thereby enabling immediate re-implantation as autologous TEHV. Its long-term functionality 
proven, the presented one-step approach suggests a highly clinically relevant concept and 
may represent a significant step towards the routine utilization of TEHVs. These first results 
are promising and demonstrate the feasibility of using BMCs for the fabrication of TEHV. 
Moreover, utilizing the body’s natural abilities to regenerate TEHV in vivo, may greatly 
simplify, and improve the clinical feasibility of the autologous cell-based TEHV approach. 
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2.4 Transapical Aortic Implantation of Autologous Marrow Stromal Cell-
based Tissue Engineered Heart Valves – First Experiences in the Systemic 
Circulation 
Emmert MY, Weber B, Behr L, Frauenfelder T, Brokopp CE, Grunenfelder J, Falk V, 
Hoerstrup SP 
JACC Cardiovasc Interv. 2011 Jul;4(7):822-3. 
 
After the feasibility of catheter based implantation of a marrow stromal cell based, autologous 
tissue engineered heart valve in a one-step intervention was proven (98), as a next step this 
concept was tested in the high-pressure systemic circulation. 
 
While the concept of minimally invasive tissue engineered heart valve implantation has only 
been proven for the low-pressure system of the right heart so far, the idea of this proof-of 
concept acute study was to challenge the high-pressure circulation. The feasibility of 
transcatheter tissue engineered orthotopic aortic valve replacements in a one step 
intervention would be the ultimate goal to broaden the future potential of tissue engineered 
heart valve (TEHV) approaches and would define the next generation concept with a vast 
clinical impact addressing a large cohort of patients. However, when taking the more 
complex anatomic conditions due to the coronary perfusion into account, as a first step, 
potential non-TEHV related, technical complications were avoided by implanting the valve in 
a supra-coronary position.  
Once more, within a one-step intervention tissue-engineered, living heart valves generated 
from biodegradable scaffolds and seeded with autologous bone-marrow derived 
mononuclear cells, were integrated into self-expanding nitinol stents (20mmx30mm) and 
transapically delivered into the descending aorta  (distal to the brachiocephalic trunk) and 
brachiocephalic trunk of sheep. Prior to implantation, native valve insufficiency was created 
by applying the Hufnagel procedure an accepted technique to induce heart valve 
incompetence (99) (figure 10). After successful deployment, the optimal positioning and 
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valve functionality were confirmed using fluoroscopy, computed-tomography (CT) and trans-
esophageal echocardiography. The crimping-time of the TEHVs was 15±2 minutes and the 
overall duration of this one-step intervention from the preparation of cells to the successful 
delivery was approximately two hours. In detail, the TEHVs demonstrated excellent in- vivo 
functionality with well defined leaflets showing sufficient coaptation. These results were 
confirmed by post-mortem analysis displaying fully intact TEHVs without any signs of leaflet-
rupture, microstructure damage or thrombus formation. 
 
Figure 10: Concept of One-Step Procedure for minimally invasive tissue engineered heart 
valve implantation into the systemic circulation: Within one procedure tissue-engineered, living 
heart valves (TEHV) fabricated from biodegradable scaffolds seeded with autologous bone-marrow 
derived mononuclear cells (a/inset), were integrated into self-expanding nitinol stents (20mm x 
30mm) and transapically delivered into the descending aorta (distal to the brachiocephalic trunk) of 
sheep (a). Native valve incompetence was created by applying the Hufnagel procedure prior to 
implantation (a). After successful deployment (b-c), valve-function and optimal positioning were 
confirmed using fluoroscopy (b), computed-tomography (CT) (d-e/inset) and echocardiography (f-m). 
 
Based on these promising results, in a further step, the orthotopic application of this one-
step intervention concept was challenged. After development and detailed adaption of the 
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TEHV design to the anatomic conditions of an orthotopic aortic valve, in a subsequent trial 
(n=12), marrow stromal cell based tissue engineered heart valves were for the first time 
implanted into the orthotopic position of the high pressure system using sophisticated 
transcatheter delivery systems (figure 11). 
In all twelve sheep of this proof-of concept trial the implantation was successful and valve 
functionality was confirmed using fluoroscopy and trans-esophageal echocardiography. 
While displaying an ideal opening and closing behaviour with a sufficient coaptation and a 
low pressure gradient (max 11mmHg), there were no signs of coronary occlusion or mal 
perfusion. In addition, mitral valve functionality was confirmed without any signs of 
regurgitation due to the stent expansion (Emmert et al, unpublished data).  
 
Figure 11: First orthotopic, transapical, tissue-engineered heart valve implantation into the 
aortic position: Based on the one-step procedure, marrow stromal cell based tissue engineered heart 
valves (A) were transapically implanted into the orthotopic, aortic position. Optimal positioning was 
confirmed using 3D computed tomography reconstruction imagery (B) and fluoroscopy (G). In the 
trans oesophageal echocardiography the implanted heart valves displayed excellent functionality with 
sufficient opening and closing (C-F) which was also confirmed in the fluoroscopy (H). In particular, 
there were no signs of coronary occlusion or perfusion compromise (Emmert et al, unpublished data). 
 
So far, successful TEHV implantations have only been reported for the low-pressure system. 
These are the first reports demonstrating the feasibility of the minimal-invasive, catheter-
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assisted implantation of TEHV into the systemic circulation with an adequate valvular 
functionality based on an easily accessible, clinically relevant cell-source (25, 34) and 
minimally-invasive techniques for both, cell-harvest and delivery. Its long term durability 
proven, such autologous and living heart valves may hold potential to overcome the 
limitations of the currently used bioprosthetic valves inherently prone to calcification and 
progressive dysfunctional degeneration. 
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2.5 Fetal Transapical Stent Delivery into the Pulmonary Artery: Prospects for 
prenatal heart valve implantation 
Emmert MY*, Weber B*, Behr L, Brokopp CE, Frauenfelder T, Kretschmar O, Falk V, 
Hoerstrup SP. Fetal Transapical Stent Delivery into the Pulmonary Artery: Prospects for 
prenatal heart valve implantation. 
Eur J Cardiothorac Surg. 2011 Jul 7. [Epub ahead of print]; *contributed equally 
 
For congenital applications, the concept of autologous tissue engineered heart valves may 
play a crucial role providing next generation constructs due to their high capacity of growth. 
Importantly, the prenatal correction of congenital cardiac defects, as a surgical repair at the 
earliest point in time, would be desirable and may be associated with significant therapeutic 
advantages with regards to less intrauterine cardiac mal-development, reduction of severity 
of postnatal disease and enhanced (scarless) healing. Therefore, the relief of obstructive 
malformations, such as heart valve stenoses, using interventional procedures has been 
suggested to promote functional recovery of the affected ventricle (100-102). 
In recent pre-clinical as well as pioneering clinical attempts the principal feasibility of fetal 
cardiac interventions has been reported, but has mainly focused on percutaneous and/or 
trans-uterine interventional approaches for treating severe aortic and pulmonary stenoses 
(37, 101-104), while open fetal cardiac surgery for valvotomy has not yet been successfully 
achieved. In 2008, Schmidt and associates (105) already demonstrated the feasibility of 
percutaneous ultrasound-guided cardiac stenting of the atrial septum in the ovine fetal 
model.  
In this pilot study, the principal technical feasibility and acute safety of an intra-uterine, 
catheter-based transapical stent implantation into the pulmonary artery of fetal sheep was 
assessed using a novel fetal hybrid intervention technique which could serve as a potential 
future route for minimally invasive prenatal heart valve implantation procedures.  
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In brief, pregnant Pre-Alp sheep between 122 to 128 days’ gestation underwent a midline 
laparotomy. The fetus was left in utero or partially externalized and its chest was opened via 
a left-sided mini-thoracotomy. The fetal heart was cannulated and a guide-wire was 
introduced through the ductus arteriosus into the aorta. A 14-French delivery system was 
then mounted onto the guide-wire and advanced to the defined landing zone located 3.0-5.0 
mm distal to the pulmonary valve annulus, where the stent was delivered. The positioning of 
the stent was confirmed using echocardiography, angiography as well as computed 
tomography. Although the introduction of the delivery device into the right ventricle was 
difficult in all fetuses and significant blood loss occurred in one of the animals, the stent 
deployment was successful in all animals and all fetuses survived. The surgical procedure 
was approximately 60 minutes, lasting from maternal laparotomy to the end of post-
deployment in vivo evaluation. In all animals contrast angiography displayed normal 
perfusion of the pulmonary vasculature as well as the ductus arteriosus and no fetal cardiac 
arrhythmia or bradycardia was observed during the procedures.  
In one of the fetuses (F1) the stent was deployed supra-valvular into the pulmonary artery. 
While an initial echo analysis confirmed the stent position clearly proximal to the ductus 
arterious Botalli (DAB), at angiography the distal stent ending was detected to reach into the 
proximal part of the DAB, indicating a slight stent migration after deployment. However, as 
confirmed by echo and angiography this migration did not compromise the DAB or PA 
perfusion in this fetus. In another fetus (F2) echocardiography revealed that one of the 
pulmonary valvular leaflets could not be fully identified suggesting some impairment of the 
cusp by the proximal stents struts. In the third fetus (F3) no signs of migration or pulmonary 
cusp impairment were found in vivo indicating optimal positioning.  
After in vivo assessment, fetuses were harvested and examined with regard to stent position, 
native leaflet impairment or further procedural complications. In all fetuses post mortem 
analysis revealed strut impregnations on the wall of the pulmonary artery, but lacking any 
laceration or perforation of the vessel wall. In one fetus (F2) the intraoperative sonographic 
finding of a too proximal stent positioning could be confirmed as one of the native pulmonary 
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leaflets was partly impaired by one of the proximal stent strut endings. Also in fetus F1 the 
angiographic stent position could be confirmed with the distal stent ending reaching into in 
the proximal DAB. In fetus F3 the stent was situated in the distal pulmonary artery not 
covering any of the native pulmonary leaflets. No signs for thoracic bleeding or stent-
associated obstruction were observed. 
The presented results show the principal technical feasibility of a fetal stent implantation via a 
catheter-based technique using the transapical route. Even if percutaneous or fetoscopic 
transapical cardiac approaches would be desirable, they lack control of direct fetal cardiac 
hemorrhage – a major issue in fetal cardiac catheterization. The presented trans-uterine 
open-chest closed-heart hybrid technique represents a possible alternative for future 
approaches, also allowing for the insertion of large devices, such as heart valve delivery 
systems. Further long-term studies are necessary to evaluate fetal myocardial tolerance and 
long-term survival of the presented technique before it may be applied to the clinical setting 
and could serve as a potential future route for minimally invasive prenatal heart valve 
implantation procedures. 
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Figure 12: The fetal open-chest in-utero transapical hybrid technique. After exteriorization of 
the uterus (A), a small incision was made in the uterine wall (B, *A-C: uterus), and the festal chest 
was opened (C). The 16 Gauge catheter was inserted into the apex of the right ventricle (F) and 
the delivery system is advanced to the landing zone. The stent is then deployed supra-valvular 
into the distal portion of the pulmonary artery (D-F). 
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3. Summary of Habilitation Thesis 
 
Valvular heart disease represents a major cause of morbidity and mortality worldwide. 
Minimally-invasive valve implantation techniques are rapidly evolving as alternative treatment 
option for the management of patients with valvular heart disease. However, despite these 
technical advances, the currently available valvular prostheses for valve replacement 
procedures are bio-prosthetic and as such inherently prone to calcification and progressive 
dysfunctional degeneration. Tissue engineering technologies aiming at the fabrication of cell 
based living heart valves have created substantial clinical hope and expectations to 
overcome these limitations. Particularly for pediatric applications, the growth potential of 
tissue engineered heart valves addresses an unmet medical need and may broaden the 
future clinical application of trans-catheter valves beyond elderly high-risk patients. 
Furthermore the combination with the specific use of stem cells may further increase the 
regenerative potential of tissue-engineered constructs. In particular, marrow stromal derived 
stem cells have been repeatedly suggested to represent an ideal cell source for 
cardiovascular tissue engineering. A clinically relevant heart valve tissue engineering 
concept would ideally comprise both minimally-invasive techniques for cell harvest and valve 
implantation. 
The articles summarized here, demonstrate the systematic development of clinically relevant 
tissue engineered heart valve concepts by combining the use of stem cells, state-of-the-art 
tissue engineering protocols and minimally invasive valve implantation techniques. 
  
In the article `Minimally-Invasive Implantation of Living Tissue Engineered Heart Valves - A 
Comprehensive Approach from Autologous Vascular Cells to Stem Cells` (Schmidt, 
…Emmert et al., 2010) for the first time, the principal feasibility of merging tissue engineering 
and minimally-invasive valve replacement technologies using adult stem cells was 
successfully demonstrated. Tri-leaflet heart valves fabricated from biodegradable synthetic 
scaffolds and autologous vascular or stem cells were integrated in self-expanding stents and 
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minimally-invasively implanted as pulmonary valve replacements in sheep. In vivo 
functionality was confirmed for up to eight weeks and histology revealed layered neo-tissues 
with endothelialized surfaces after sacrifice. 
As a meticulous understanding of the underlying mechanisms of neo-tissue formation and 
matrix remodeling is crucial with regards to future clinical applications of tissue engineering 
technologies, matrix metalloproteinases (MMP) were identified to play a key role of matrix 
remodeling, tissue homeostasis and functional growth. Based on a previous study elucidating 
the concept of growth (Hoerstrup et al, 2006), MMPs were demonstrated to contribute to 
increased matrix remodeling, native analogous tissue formation and functional growth in 
tissue-engineered vascular grafts (TEVGs) in vivo in a growing lamb model (`Tissue 
engineered vascular graft remodeling in a growing lamb model: expression of matrix 
metalloproteinases` - Cummings, …Emmert et al, 2011). 
 
In a further step, the feasibility of generating injectable, marrow stromal cell-based, 
autologous, living tissue engineered heart valves (TEHVs) and implantation in a one-step 
intervention in non-human primates was investigated (`Injectable living marrow stromal cell-
based autologous tissue engineered heart valves: first experiences with a one-step 
intervention in primates` - Emmert*, Weber* et al, 2011; *contributed equally). Within the 
same intervention, autologous bone marrow-derived mononuclear cells were harvested, 
seeded on biodegradable scaffolds, integrated into self-expanding nitinol stents and 
transapically implanted as pulmonary valve replacements into non-human primates. For the 
first time, the feasibility of heart valve tissue engineering based on a minimally invasive 
technique for both cell harvest and valve delivery in a one-step intervention could be 
demonstrated while avoiding any need of an in vitro bio-reactor phase.  
Based on this novel approach and in order to broaden the future clinical application of trans-
catheter tissue engineered heart valves, in a subsequent step this concept was also 
successfully applied to the high-pressure system of the systemic circulation (`Transapical 
Aortic Implantation of Autologous Marrow Stromal Cell-based Tissue Engineered Heart 
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Valves – First Experiences in the Systemic Circulation` - Emmert, Weber et al, 2011). The 
fabricated TEHVs were transapically delivered into the descending aorta (distal to the 
brachiocephalic-trunk) and brachiocephalic-trunk of sheep. To achieve a sufficient loading, 
native valve incompetence was created by applying the Hufnagel procedure prior to 
implantation. Post mortem analysis displayed fully intact TEHVs and in particular well defined 
leaflets showing coaptation, while there were no signs of pressure damage, leaflet rupture or 
thrombus formation detectable. 
 
In the context of pediatric applications, TEHVs appear to be particularly beneficial due to 
their high capacity of growth. Importantly, the prenatal correction of congenital cardiac 
defects, as a surgical repair at the earliest time point, would be desirable and may be 
associated with significant therapeutic advantages with regards to less intrauterine cardiac 
mal-development, reduction of severity of postnatal disease and enhanced (scarless) 
healing. Therefore, as a next step in the frame of a pilot study, the principal technical 
feasibility and acute safety of intra-uterine, fetal stent implantation into the pulmonary artery 
via a catheter-based transapical hybrid technique in an ovine fetal model was demonstrated, 
being the first step towards possible future minimally invasive prenatal heart valve 
implantation procedures (`Fetal Transapical Stent Delivery into the Pulmonary Artery: 
Prospects for prenatal heart valve implantation` - Emmert*, Weber* et al, 2011; *contributed 
equally). 
 
The results of this habilitation thesis demonstrate that the combination stem-cell based heart 
valve tissue engineering and minimally invasive implantation techniques represents a 
promising, clinically relevant approach which may be particularly beneficial for paediatric 
patients due to its high capacity of growth. Its long-term durability proven, such autologous 
and living heart valves with repair properties may represent the next generation of 
transcatheter heart valves overcoming the limitations of the currently used prostheses. 
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4. Conclusions & Outlook 
 
More than 50 years ago, Dr. D.E. Harken, a pioneer in the field of heart valve surgery, was 
the first who successfully implanted a heart valve into the subcoronary, aortic position in a 
patient suffering from severe aortic stenosis (106). After this milestone achievement 
representing a breakthrough in the field of heart valve diseases, the evolution of heart valve 
prostheses has undergone rapid changes and made significant advances over the past 
decades (figure 13). While the initial valve prostheses were fabricated from mechanical 
components based on concept models derived from the aviation industry, the field has 
changed stepwise into the direction of biological prostheses over the past years. In parallel, 
even though the conventional surgical technique of heart valve replacement has served as a 
very safe and reliable method for many years, the valve replacement techniques have 
continuously changed into the direction of minimally invasive, transcatheter-based 
approaches (figure 13).  
 
Despite these tremendous advances over the past fifty years with regards to the refinement 
of heart valve prostheses as well as the surgical technologies for implantation, major issues 
have remained unsolved. Although current available prostheses demonstrate excellent 
structural durability (9, 12-14), the currently available bio-prostheses for minimally invasive, 
transcatheter-based procedures are still inherently prone to progressive degeneration and 
calcification requiring redo surgery within 10-15 years after implantation and therefore 
suggesting their clinical indication primarily in the elderly, high-risk patients (7). Furthermore, 
the lack of growth capacity as well as in vivo repair and remodeling properties remain key 
issues with particular regards to congenital applications. 
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Figure 13: The Evolution of Heart Valve Prostheses: After Dr. D.E. Harken was the first who 
successfully implanted a heart valve into the subcoronary, aortic position in a patient suffering from 
severe aortic stenosis in 1960, the evolution heart valve prostheses has undergone rapid changes and 
made significant advances over the past decades. In parallel, also the valve replacement techniques 
have continuously changed into the direction of minimally invasive, transcatheter-based approaches. 
The concept of heart valve tissue engineering offering the potential of growth and remodeling, may 
represent an ideal, next generation therapy concept for trans-catheter heart valve replacements 
(Emmert & Hoerstrup; unpublished concept figure) 
 
Despite the rapid evolution in the treatment of valvular diseases, these limitations clearly 
indicate that current therapy concepts of heart valve replacements are still suboptimal and 
the ideal approach needs to be developed (11). Interestingly, it was also Dr. D.E. Harken, 
who already defined in the 1950th the essential characteristics of the ideal valve prosthesis. 
In his so-called `Ten Commandments` (107), the pioneer Harken summarized the major 
aspects of the ideal heart valve construct, including durability, absence of thrombogenicity, 
resistance to infections, lack of antigenicity, and the potential of growth. He stated the key 
characteristics of natural, living, heart valves (107).  
To overcome these limitations, the concept of heart valve tissue engineering has been 
suggested as a promising approach and has created substantial hope as well as 
expectations. The major goal of tissue engineering concept is to fabricate living, autologous 
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heart valves exactly comprising the properties of their native counterpart. The idea of this 
tissue engineering heart valve concept which is not associated with any immune reaction, 
thromboembolic events or degeneration processes, while offering the potential of growth and 
remodeling, may represent the ideal next generation therapy concept for heart valve 
replacements. 
In this habilitation thesis, the principal feasibility and safety of heart valve tissue engineering 
concepts in a translational, preclinical setting is systematically demonstrated. The data 
presented provide systematic evidence of the development of clinically relevant tissue 
engineered heart valve concepts by combining the use of stem cells, state-of-the-art tissue 
engineering protocols and minimally invasive valve implantation techniques. These strategies 
may represent a promising, future approach being particularly beneficial for paediatric 
patients due to its high capacity of growth addressing an unmet medical and may prevent 
children with congenital malformations from high risk redo operations. Furthermore, the 
implementation of these concepts into the clinical routine may also have a vast impact with 
regards to economic as well as social aspects. In both scenarios the congenital as well as 
adult setting, the application of autologous, living heart valves may prevent the patients from 
the necessity of reoperations saving a lot of financial and logistical resources. Subsequently, 
the introduced concept of using endogenous stem cell potential of a patient in a one-step 
intervention, while avoiding any need for an expensive and logistically demanding in vitro bio-
reactor phase, may represent an ideal and highly efficient concept especially for patients in 
the developing countries with limited financial and technical resources. 
However, despite of its huge potential to significantly improve the therapy of valvular heart 
disease and despite all enthusiasm, several key steps have to be completed before the 
standardized implementation of heart valve tissue engineering into the clinical arena will be 
possible. Besides the principal demonstration of the long-term safety and efficacy of an 
implanted construct to prevent from catastrophic failure, pre-clinical guidelines defining how 
to characterize the safety, efficacy, and quality of a tissue engineered construct need to be 
established (108). In brief, future research directions (summarized in table 2) should focus on 
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the fundamental understanding of underlying remodeling and repair mechanisms including a 
better knowledge of the biochemical and immunological characteristics of the cells and 
tissues undergoing in vitro growth. In addition, the disposition of implanted structures to 
typical biomaterial tissue interactions of medical devices, such as calcification, thrombosis 
and excessive inflammatory response have to be elucidated (109). 
Another key consideration is the important aspect that currently available valve prostheses 
reveal a certain, predictable behaviour with regards to durability and biocompatibility; while 
tissue engineered constructs, potentially relying on in vivo remodeling, may show substantial 
variability among different patients due to the heterogeneity of the physiological tissue 
remodeling potential. For this reason, the development of sufficient clinical guidelines 
defining the inclusion criteria for specific patient cohorts with regards to safety, efficacy and 
quality of the engineered constructs is mandatory (109). Therefore, the identification of 
biomarkers as independent predictors as well as conventional or innovative imaging 
modalities may represent useful and important tools to assess the success, but also the 
failure of an implanted construct.  
From the logistical point of view when considering initial clinical trials (pilot study), laboratory 
processes and logistics need to be adapted in according to the good manufacturing practice 
(GMP) guidelines providing a maximum degree of process control and bio-safety. Ideally, in 
the context of a classical tissue engineering approach, an exemplary algorithm would 
comprise the following steps: (a) isolation of autologous cells from designated sources (i.e. 
by a bone marrow puncture or adipose tissue aspiration under local anesthesia), (b) 
differentiation and expansion of cells and engineering of a heart valve prostheses in vitro; 
and (c) following defined quality criteria (biological, histological, bio-safety), re-implantation of 
living autologous valve replacements into patients after a defined time period of a maximum 
of six to eight weeks (109). 
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Challenges Research Directions 
TEHV components and their interactions are 
complex, heterogeneous and dynamic 
Define cell/scaffold/bioreactor combinations that 
optimize construct composition and properties 
(in vitro) 
 
Correlation of in vitro generated construct 
structure and properties with in vivo outcomes 
has not been demonstrated 
 
Determine and validate correlations between in 
vitro conditions, elements, structure, properties 
and in vivo function 
Quality control of construct structure and 
function is likely to be difficult 
Develop guidelines, tools and metrics for the 
pre-implantation characterization of TEHV 
structure, function and quality 
 
Animal models may not reliably predict human 
outcomes 
Develop and validate animal models that will test 
key biological processes and correlate with 
human outcomes 
 
TEHV structure is likely to be evolving in vivo 
and ongoing function may be less predictable 
than with conventional valve replacement 
technology 
 
Develop guidelines, tools and metrics for the in 
vivo characterization of dynamic TEHV structure, 
function and quality 
TEHV function will depend upon patient 
response to implantation and integration with the 
recipient’s tissues more than with conventional 
valve replacement, and individual patient 
responses may be highly variable 
 
Identify/validate biomarkers both predictive of 
and assess patient variability in implant 
success/failure and capable of non-invasive in 
vivo monitoring and potential control 
Remodeling processes after implantation may 
release or change seeded cells and recruit host 
cells 
 
Develop tools to monitor the fate of transplanted 
and endogenous cells (location, function, 
viability, phenotype) 
Regulatory processes and approaches are not 
yet well established 
Create suitable regulatory approaches to 
engineered tissue valves that will ensure safety 
and efficacy 
 
Table 2: Key steps and future research challenges for the clinical translation of Heart Valve 
Tissue Engineering (adapted from Schoen, Review; Current Opinion in Biotechnology, 2011);  
TEHV = Tissue Engineered Heart Valve 
 
 
In conclusion, the data presented in this habilitation thesis systematically demonstrate that 
the combination of sophisticated stem cell approaches, state-of-the-art tissue engineering 
protocols and minimally invasive valve implantation techniques represents a promising, 
clinically relevant approach which may be particularly beneficial for paediatric patients. Its 
long-term feasibility proven and considering the above mentioned future research 
challenges, the concept of autologous, living heart valves may represent the next generation 
of trans-catheter heart valves overcoming the limitations of the currently used prostheses 
and may be rapidly translated into a clinical setting. 
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